{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,10,3]],"date-time":"2023-10-03T09:12:23Z","timestamp":1696324343906},"reference-count":23,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","license":[{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Transplantation Direct"],"published-print":{"date-parts":[[2019,1]]},"abstract":"<jats:sec>\n            <jats:title>Introduction<\/jats:title>\n            <jats:p>Prolonged-release tacrolimus (PR-TAC) was associated with improved renal function after transplantation when compared to immediate-release tacrolimus (IR-TAC) although evidence is still scarce. This study aimed to compare clinical outcomes and treatment costs in patients who converted from IR-TAC to PR-TAC during the first year after renal transplantation (RT) (early converters [EC]) or after that period (late converters [LC]).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>We performed a retrospective study including 79 patients (EC, 39; LC, 41) which were followed up over 60 months. A mixed-effects approach was used to investigate the differences between both groups regarding renal and metabolic outcomes as well as treatment costs.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>The median time from RT to conversion was 3 months for EC and 25 months for LC. For both EC and LC, a significant increase in estimated glomerular filtration rate was observed after conversion (5.2 and 4.9 mL\/min per 1.73 m<jats:sup>2<\/jats:sup>, respectively). During the first year after RT, EC presented a higher estimated glomerular filtration rate and inferior tacrolimus trough levels when compared to LC, with higher mean treatment costs associated. However, thereafter, these outcomes were similar between groups over the remaining time. At the end of follow-up, no significant differences were found regarding allograft acute rejection (2.6% and 2.4%), new-onset diabetes (15.7% vs 12.2%) or cardiovascular events (5.2% vs 7.3%).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>There was a significant benefit on renal function after conversion from IR-TAC to PR-TAC. During the first year after RT, EC presented improved renal function, but higher treatment costs. None of these differences persisted at the end of follow-up.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/txd.0000000000000853","type":"journal-article","created":{"date-parts":[[2018,12,27]],"date-time":"2018-12-27T19:23:18Z","timestamp":1545938598000},"page":"e417","source":"Crossref","is-referenced-by-count":0,"title":["Early Versus Late Conversion From Immediate to Prolonged-Release Tacrolimus After Renal Transplantation: Clinical Effects and Treatment Costs"],"prefix":"10.1097","volume":"5","author":[{"given":"Lu\u00eds","family":"Mendon\u00e7a","sequence":"first","affiliation":[{"name":"Department of Nephrology, S\u00e3o Jo\u00e3o Hospital Center, EPE, Alameda Prof. Hern\u00e2ni Monteiro, Porto, Portugal."}]},{"given":"Hugo","family":"Diniz","sequence":"additional","affiliation":[{"name":"Department of Nephrology, S\u00e3o Jo\u00e3o Hospital Center, EPE, Alameda Prof. Hern\u00e2ni Monteiro, Porto, Portugal."}]},{"given":"Jos\u00e9","family":"Silvano","sequence":"additional","affiliation":[{"name":"Department of Nephrology, S\u00e3o Jo\u00e3o Hospital Center, EPE, Alameda Prof. Hern\u00e2ni Monteiro, Porto, Portugal."}]},{"given":"Sofia","family":"Marques","sequence":"additional","affiliation":[{"name":"Department of Nephrology, S\u00e3o Jo\u00e3o Hospital Center, EPE, Alameda Prof. Hern\u00e2ni Monteiro, Porto, Portugal."}]},{"given":"Susana","family":"Sampaio","sequence":"additional","affiliation":[]},{"given":"Manuel","family":"Pestana","sequence":"additional","affiliation":[]}],"member":"276","published-online":{"date-parts":[[2019,1]]},"reference":[{"key":"bib1-20231002","first-page":"S1","article-title":"KDIGO clinical practice guideline for the care of kidney transplant recipients","year":"2009","journal-title":"Am J Transplant"},{"key":"bib2-20231002","doi-asserted-by":"crossref","first-page":"2562","DOI":"10.1056\/NEJMoa067411","article-title":"Reduced exposure to calcineurin inhibitors in renal transplantation","volume":"357","year":"2007","journal-title":"N Engl J Med"},{"key":"bib3-20231002","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1517\/14740338.2015.1083974","article-title":"The safety of calcineurin inhibitors for kidney-transplant patients","volume":"14","year":"2015","journal-title":"Expert Opin Drug Saf"},{"key":"bib4-20231002","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1097\/FTD.0b013e318167909a","article-title":"First clinical experience with the new once-daily formulation of tacrolimus","volume":"30","year":"2008","journal-title":"Ther Drug Monit"},{"key":"bib5-20231002","first-page":"391","article-title":"Budget impact of switching from an immediate-release to a prolonged-release formulation of tacrolimus in renal transplant recipients in the UK based on differences in adherence","volume":"8","year":"2014","journal-title":"Patient Prefer Adherence"},{"key":"bib6-20231002","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1097\/01.TP.0000437561.31212.0e","article-title":"Lower variability in 24-hour exposure during once-daily compared to twice-daily tacrolimus formulation in kidney transplantation","volume":"97","year":"2014","journal-title":"Transplantation"},{"key":"bib7-20231002","doi-asserted-by":"crossref","first-page":"2950","DOI":"10.1016\/j.transproceed.2011.07.014","article-title":"Improved kidney graft function after conversion from twice daily tacrolimus to a once daily prolonged-release formulation","volume":"43","year":"2011","journal-title":"Transplant Proc"},{"key":"bib8-20231002","doi-asserted-by":"crossref","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","article-title":"A new equation to estimate glomerular filtration rate","volume":"150","year":"2009","journal-title":"Ann Intern Med"},{"key":"bib9-20231002","doi-asserted-by":"crossref","first-page":"181","DOI":"10.2337\/dc11-1230","article-title":"New-onset diabetes after renal transplantation: risk assessment and management","volume":"35","year":"2012","journal-title":"Diabetes Care"},{"key":"bib10-20231002","doi-asserted-by":"crossref","first-page":"481","DOI":"10.2215\/CJN.04800908","article-title":"Calcineurin inhibitor nephrotoxicity","volume":"4","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"key":"bib11-20231002","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1053\/j.ackd.2005.11.001","article-title":"Calcineurin nephrotoxicity","volume":"13","year":"2006","journal-title":"Adv Chronic Kidney Dis"},{"key":"bib12-20231002","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1097\/TP.0b013e3182461288","article-title":"Genetic and clinical determinants of early, acute calcineurin inhibitor-related nephrotoxicity: results from a kidney transplant consortium","volume":"93","year":"2012","journal-title":"Transplantation"},{"key":"bib13-20231002","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1111\/ajt.12035","article-title":"Conversion from twice-daily tacrolimus to once-daily extended release tacrolimus (LCPT): the phase III randomized MELT trial","volume":"13","year":"2013","journal-title":"Am J Transplant"},{"key":"bib14-20231002","doi-asserted-by":"crossref","first-page":"81","DOI":"10.5414\/CP202518","article-title":"Clinical advantages including medication adherence with conversion to once-daily advagraf and sirolimus combination in stable kidney recipients","volume":"54","year":"2016","journal-title":"Int J Clin Pharmacol Ther"},{"key":"bib15-20231002","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1111\/tri.12435","article-title":"A randomized cross-over comparison of short-term exposure of once-daily extended release tacrolimus and twice-daily tacrolimus on renal function in healthy volunteers","volume":"27","year":"2014","journal-title":"Transpl Int"},{"key":"bib16-20231002","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1097\/TP.0b013e3182098ff0","article-title":"Conversion from Prograf to Advagraf among kidney transplant recipients results in sustained decrease in tacrolimus exposure","volume":"91","year":"2011","journal-title":"Transplantation"},{"key":"bib17-20231002","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1097\/TP.0b013e3182a203bd","article-title":"OSAKA trial: a randomized, controlled trial comparing tacrolimus QD and BD in kidney transplantation","volume":"96","year":"2013","journal-title":"Transplantation"},{"key":"bib18-20231002","doi-asserted-by":"crossref","first-page":"2632","DOI":"10.1111\/j.1600-6143.2010.03256.x","article-title":"Tacrolimus once daily (ADVAGRAF) versus twice daily (PROGRAF) in de novo renal transplantation: a randomized phase III study","volume":"10","year":"2010","journal-title":"Am J Transplant"},{"key":"bib19-20231002","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1111\/j.1600-6143.2007.01661.x","article-title":"One-year results with extended-release tacrolimus\/MMF, tacrolimus\/MMF and cyclosporine\/MMF in de novo kidney transplant recipients","volume":"7","year":"2007","journal-title":"Am J Transplant"},{"key":"bib20-20231002","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/S0041-1345(00)02142-4","article-title":"Experimental study of tacrolimus immunosuppression on the mode of administration: efficacy of constant intravenous infusion avoiding C(max)","volume":"33","year":"2001","journal-title":"Transplant Proc"},{"key":"bib21-20231002","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1016\/j.transproceed.2010.03.123","article-title":"Once daily tacrolimus formulation: monitoring of plasma levels, graft function, and cardiovascular risk factors","volume":"42","year":"2010","journal-title":"Transplant Proc"},{"key":"bib22-20231002","first-page":"175","article-title":"New onset diabetes after transplantation (NODAT): an overview","volume":"4","year":"2011","journal-title":"Diabetes Metab Syndr Obes"},{"key":"bib23-20231002","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1080\/13696998.2016.1189921","article-title":"A cost-utility analysis of prolonged-release tacrolimus relative to immediate-release tacrolimus and ciclosporin in liver transplant recipients in the UK","volume":"19","year":"2016","journal-title":"J Med Econ"}],"container-title":["Transplantation Direct"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/01845228-201901000-00005","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,2]],"date-time":"2023-10-02T07:26:07Z","timestamp":1696231567000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/01845228-201901000-00005"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1]]},"references-count":23,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.1097\/txd.0000000000000853","relation":{},"ISSN":["2373-8731"],"issn-type":[{"value":"2373-8731","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1]]}}}